As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Vaxcyte Inc. The largest reported stake is Fmr LLC's, at 14.4%. 16 filings are on record since August 6, 2025 (Schedule 13G/A, August 6, 2026).
Sell to companies like Vaxcyte Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 17,359,465 · Shared voting: 0 · Sole dispositive: 18,136,166 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-06
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 9.6% · SCHEDULE 13G/A
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 18,040,375 · Sole dispositive: 0 · Shared dispositive: 18,040,375 · SCHEDULE 13G/A, 2026-08-11
- · Holder: JANUS HENDERSON GROUP Ltd. · Percent: 0.1% · SCHEDULE 13G/A
- · Reporting person: Fmr LLC · Sole voting: 18,886,452 · Shared voting: 0 · Sole dispositive: 20,798,907 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-06
Vaxcyte Inc has 16 Schedule 13D or 13G filings on record since 2025-08-06. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 14.4% | 20,798,907 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| JANUS HENDERSON GROUP Ltd. | 12.1% | 18,040,375 | SCHEDULE 13G/A, 2026-08-11 | 2026-07-31 |
| T. Rowe Price Investment Management, Inc. | 11.6% | 18,136,166 | SCHEDULE 13G/A, 2026-11-06 | 2026-10-31 |
| RA Capital Management, L.P. | 8.9% | 12,974,599 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Vanguard Capital Management | 5.03% | 7,252,053 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Vaxcyte Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Vaxcyte Inc and the records around it.
Vaxcyte Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Vaxcyte Inc
Get an email when Vaxcyte Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vaxcyte Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vaxcyte Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vaxcyte Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 18,886,452 | 0 | 20,798,907 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 20,798,907 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| JANUS HENDERSON GROUP Ltd. | 0 | 18,040,375 | 0 | 18,040,375 | SCHEDULE 13G/A, 2026-08-11 |
| T. Rowe Price Investment Management, Inc. | 17,359,465 | 0 | 18,136,166 | 0 | SCHEDULE 13G/A, 2026-11-06 |
| RA Capital Management, L.P. | 0 | 12,974,599 | 0 | 12,974,599 | SCHEDULE 13G/A, 2026-05-15 |
| Peter Kolchinsky | 0 | 12,974,599 | 0 | 12,974,599 | SCHEDULE 13G/A, 2026-05-15 |
| Rajeev Shah | 0 | 12,974,599 | 0 | 12,974,599 | SCHEDULE 13G/A, 2026-05-15 |
| RA Capital Healthcare Fund, L.P. | 0 | 12,699,089 | 0 | 12,699,089 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Vaxcyte Inc by CUSIP 92243G108 and gives its principal executive office as 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA 94070 (SCHEDULE 13G/A, 2026-11-06).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-05-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Fmr LLC | 9.4% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 11.4% | SCHEDULE 13G/A |
| 2025-09-08 | Fmr LLC | 10.1% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 10.1% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Investment Management, Inc. | 6.4% | SCHEDULE 13G |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 8.6% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Vanguard Capital Management | 5.03% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 11.4% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 11.5% | SCHEDULE 13G/A |
| 2026-05-15 | RA Capital Management, L.P. | 8.9% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 14.4% | SCHEDULE 13G/A |
| 2026-08-07 | JANUS HENDERSON GROUP Ltd. | 0.1% | SCHEDULE 13G/A |
| 2026-08-11 | JANUS HENDERSON GROUP Ltd. | 12.1% | SCHEDULE 13G/A |
| 2026-11-06 | T. Rowe Price Investment Management, Inc. | 9.6% | SCHEDULE 13G/A |
| 2026-11-06 | T. Rowe Price Investment Management, Inc. | 11.6% | SCHEDULE 13G/A |
Questions about who owns Vaxcyte Inc
Who owns Vaxcyte Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Vaxcyte Inc: Fmr LLC (14.4%, Schedule 13G/A, filed 2026-08-06), JANUS HENDERSON GROUP Ltd. (12.1%, Schedule 13G/A, filed 2026-08-11), T. Rowe Price Investment Management, Inc. (11.6%, Schedule 13G/A, filed 2026-11-06), RA Capital Management, L.P. (8.9%, Schedule 13G/A, filed 2026-05-15) and Vanguard Capital Management (5.03%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Vaxcyte Inc?
By the share each holder's latest filing reports, the largest holders of Vaxcyte Inc on this page are Fmr LLC (14.4%), JANUS HENDERSON GROUP Ltd. (12.1%) and T. Rowe Price Investment Management, Inc. (11.6%).
When did Fmr LLC buy into Vaxcyte Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-08-06, reporting 9.4%; its latest, Schedule 13G/A filed 2026-08-06, reports 14.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Vaxcyte Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 15, 2026 | Leadership change: Heath Lukatch departs, and 1 more | — | Leadership changes | Source |
| June 23, 2026 | Leadership change: Jacks Lee departs, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Vaxcyte Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.